We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

By LabMedica International staff writers
Posted on 08 Aug 2025

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. More...

Yet, current tools used in healthcare to estimate cardiovascular risk rely on clinical variables that can be imprecise. Now, a new study has identified blood-based biomarkers that significantly improve the prediction of future cardiovascular disease in this population.

A research team led by Lund University (Lund, Sweden) conducted the study, which focused on DNA methylation as a way to detect epigenetic biomarkers in blood. Researchers tracked 752 newly diagnosed individuals from the diabetes cohort ANDIS (All New Diabetics in Skåne) who had no prior cardiovascular disease. Over 7 years, the researchers followed participants' cardiovascular health and studied chemical changes in their genomes.

The team discovered over 400 sites in the blood where DNA methylation was altered. Of these, 87 sites were used to create a scoring system that assesses individual risk for cardiovascular complications. The test showed a strong negative predictive value, with 96% accuracy in identifying those unlikely to develop heart disease.

These findings, published in Cell Reports Medicine, could transform how clinicians identify at-risk patients. Individuals flagged as high risk could receive earlier support in areas such as diet, exercise, weight control, blood sugar management, and cardiovascular protection. The researchers now aim to develop a clinical kit that allows DNA methylation to be measured through a simple blood sample.

"Healthcare today uses clinical variables such as age, gender, blood pressure, smoking, harmful cholesterol, long-term blood sugar, and kidney function to estimate the risk of future cardiovascular disease, but it is a rather blunt tool. If you add DNA methylation, you have a much better measure of future risk," said Charlotte Ling, senior author of the study. “We therefore want to develop a kit for clinical use, so that a simple blood sample can measure DNA methylation and predict who is at risk of becoming ill using the scoring scale.”

Related Links:
Lund University


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.